ES3028360T3 - Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof - Google Patents

Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof Download PDF

Info

Publication number
ES3028360T3
ES3028360T3 ES18824477T ES18824477T ES3028360T3 ES 3028360 T3 ES3028360 T3 ES 3028360T3 ES 18824477 T ES18824477 T ES 18824477T ES 18824477 T ES18824477 T ES 18824477T ES 3028360 T3 ES3028360 T3 ES 3028360T3
Authority
ES
Spain
Prior art keywords
compound
mmol
added
cancer
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18824477T
Other languages
English (en)
Spanish (es)
Inventor
Yihan Wang
Zhiqiang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Targetrx Inc
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Application granted granted Critical
Publication of ES3028360T3 publication Critical patent/ES3028360T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18824477T 2017-06-26 2018-06-25 Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof Active ES3028360T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710493544 2017-06-26
PCT/CN2018/092588 WO2019001383A1 (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Publications (1)

Publication Number Publication Date
ES3028360T3 true ES3028360T3 (en) 2025-06-19

Family

ID=63772870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18824477T Active ES3028360T3 (en) 2017-06-26 2018-06-25 Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof

Country Status (6)

Country Link
US (1) US11718611B2 (enExample)
EP (1) EP3626241B1 (enExample)
JP (2) JP7374496B2 (enExample)
CN (2) CN110759908B (enExample)
ES (1) ES3028360T3 (enExample)
WO (1) WO2019001383A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN115286689B (zh) * 2022-09-29 2023-01-06 上海睿跃生物科技有限公司 靶向降解Bcl-2蛋白的化合物及其应用和药物
CN115872963A (zh) * 2022-12-27 2023-03-31 南京哈柏医药科技有限公司 一种维奈托克中间体的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
MY165884A (en) * 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20190225607A1 (en) * 2016-07-06 2019-07-25 Concert Pharmaceuticals, Inc. Deuterated Venetoclax

Also Published As

Publication number Publication date
EP3626241A1 (en) 2020-03-25
US11718611B2 (en) 2023-08-08
CN108658983B (zh) 2019-12-20
JP7374496B2 (ja) 2023-11-07
CN110759908A (zh) 2020-02-07
CN108658983A (zh) 2018-10-16
US20200216442A1 (en) 2020-07-09
WO2019001383A1 (zh) 2019-01-03
JP2022071077A (ja) 2022-05-13
JP2020527166A (ja) 2020-09-03
EP3626241B1 (en) 2025-04-23
CN110759908B (zh) 2021-03-12
EP3626241A4 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
ES3028360T3 (en) Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
ES2898765T3 (es) Compuestos de quinazolina sustituidos y métodos de uso de los mismos
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
ES2773138T3 (es) Derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1H-pirrolo[2,3-c]piridina como inhibidores de NIK para el tratamiento del cáncer
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
JP2021502386A (ja) Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
BR112018003634B1 (pt) Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
US9273005B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2020114388A1 (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
WO2018086446A1 (zh) 具有穿过血脑屏障能力的取代的喹唑啉化合物
CN109851638B (zh) 取代的二氨基嘧啶化合物
PT2937344T (pt) Derivados piridinil e pirazinil-metoxi-arilo úteis como inibidores de tirosina quinase de baço (syk)
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
CN113906040B (zh) 用于治疗癌症的化合物
ES2976576T3 (es) Formas cristalinas de un inhibidor de la fosfoinositida 3-quinasa (pi3k)
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN108026046A (zh) 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
CN115368378B (zh) 取代的大环化合物及包含该化合物的组合物及其用途
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
ES2532476T3 (es) Sales de aminas orgánicas de derivados de ácido aminobenzoico, y método para su producción
EP3816162A1 (en) Diarylpyrazole compound, composition comprising same, and use thereof
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof